Novel Biomarkers of Gastrointestinal Cancer

Shimura, Takaya

doi:10.3390/cancers13071501

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Firstly, patients may be reluctant to handle fecal material. In addition, handling stool samples is challenging for both patients and investigators, and the quality of the sample collection by patients may affect the results [89]. Furthermore, as in the case of urine and blood, the biomarkers found in the stool may not be specific for GC.…”

Section: Stool Biomarkersmentioning

confidence: 99%

Biomarkers for Gastric Cancer Screening and Early Diagnosis

et al. 2021

View full text Add to dashboard Cite

Gastric cancer is one of the most common cancers worldwide, with a bad prognosis associated with late-stage diagnosis, significantly decreasing the overall survival. This highlights the importance of early detection to improve the clinical course of these patients. Although screening programs, based on endoscopic or radiologic approaches, have been useful in countries with high incidence, they are not cost-effective in low-incidence populations as a massive screening strategy. Additionally, current biomarkers used in daily routine are not specific and sensitive enough, and most of them are obtained invasively. Thus, it is imperative to discover new noninvasive biomarkers able to diagnose early-stage gastric cancer. In this context, liquid biopsy is a promising strategy. In this review, we briefly discuss some of the potential biomarkers for gastric cancer screening and diagnosis identified in blood, saliva, urine, stool, and gastric juice.

show abstract

Section: Stool Biomarkersmentioning

confidence: 99%

Biomarkers for Gastric Cancer Screening and Early Diagnosis

et al. 2021

View full text Add to dashboard Cite

show abstract

The prognostic value of microRNA‐200 family expression in digestive system tumors: A meta‐analysis and validation

Wu,

Heng,

et al. 2024

MedComm – Oncology

View full text Add to dashboard Cite

The relevance of miR‐200 family in the prognosis of digestive system tumors remains controversial. Through a systematic review of the pertinent literature using online databases including PubMed, EMBASE, The Cochrane Library, and Web of Science, our pooled‐analysis revealed that miR‐200 family downregulation was significantly correlated with poor overall survival (OS, hazard ratio [HR] > 1) and disease‐free survival (HR > 1) in digestive malignancies. Consistently, subgroup analyzes of various organ tissues, univariate analysis, gastric cancer, pancreatic cancer, and patients of American descent revealed the hazardous effects of miR‐200 family downregulation. In contrast, low miR‐200 family expression in blood samples predicted favorable OS (HR < 1). Moreover, lower expression levels of miR‐200c‐5p and miR‐429 were validated in esophageal squamous cell carcinoma (ESCC) tissues. Both the protein and messenger RNA expression levels of Paralemmin‐2 (PALM2) and Mitotic Arrest Deficient 2‐Like Protein (MAD2L1), regulated by miR‐200c‐5p, were notably higher in ESCC, and increased protein levels of PALM2 and MAD2L1 were correlated with adverse OS. PALM2 overexpression significantly enhanced ESCC cell migration. In conclusion, our study highlights the prognostic value of miR‐200 family in digestive system tumors, and the decrease of miR‐200c‐5p may promote ESCC invasion through upregulation of PALM2 and MAD2L1.

show abstract

Novel Biomarkers of Gastrointestinal Cancer

Abstract: Gastrointestinal (GI) cancer is a major cause of morbidity and mortality worldwide [...]

Cited by 2 publications

References 17 publications

Biomarkers for Gastric Cancer Screening and Early Diagnosis

Biomarkers for Gastric Cancer Screening and Early Diagnosis

The prognostic value of microRNA‐200 family expression in digestive system tumors: A meta‐analysis and validation

Contact Info

Product

Resources

About